CTOs on the Move

Immunic

www.imux.com

 
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.imux.com
  • 1200 Avenue of the Americas Suite 200
    New York, NY USA 10036
  • Phone: 332.255.9811

Executives

Name Title Contact Details

Similar Companies

International Center for Toxicology and Medicine

International Center for Toxicology and Medicine is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CORIA Laboratories

CORIA Laboratories, Ltd. is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MIND 24-7

MIND 24-7 is fundamentally changing the landscape of accessible behavioral health by offering walk-in urgent mental health and substance abuse services such as Psych Express Care, Psych Crisis Care, and Psych Progressions. MIND 24-7 fills the gap for those seeking help by being available right when they need it – 24 hours a day, 365 days a year. Using innovations in value-based care models to improve and expand access to care, MIND 24-7 not only enhances quality patient care, but reduces pressure on the system, reducing costly emergency room visits, in-patient treatment, and readmissions for crisis care.

Vitro Diagnostics

Vitro Diagnostics is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.